Zobrazeno 1 - 10
of 40
pro vyhledávání: '"Robert A. Lasser"'
Autor:
Susanne Ostrowitzki, Robert A. Lasser, Ernest Dorflinger, Philip Scheltens, Frederik Barkhof, Tania Nikolcheva, Elizabeth Ashford, Sylvie Retout, Carsten Hofmann, Paul Delmar, Gregory Klein, Mirjana Andjelkovic, Bruno Dubois, Mercè Boada, Kaj Blennow, Luca Santarelli, Paulo Fontoura, for the SCarlet RoAD Investigators
Publikováno v:
Alzheimer’s Research & Therapy, Vol 9, Iss 1, Pp 1-15 (2017)
Abstract Background Gantenerumab is a fully human monoclonal antibody that binds aggregated amyloid-β (Aβ) and removes Aβ plaques by Fc receptor-mediated phagocytosis. In the SCarlet RoAD trial, we assessed the efficacy and safety of gantenerumab
Externí odkaz:
https://doaj.org/article/e955ede30f6c4f9ea14e0090bdf6615d
Autor:
Susanne Ostrowitzki, Robert A. Lasser, Ernest Dorflinger, Philip Scheltens, Frederik Barkhof, Tania Nikolcheva, Elizabeth Ashford, Sylvie Retout, Carsten Hofmann, Paul Delmar, Gregory Klein, Mirjana Andjelkovic, Bruno Dubois, Mercè Boada, Kaj Blennow, Luca Santarelli, Paulo Fontoura, for the SCarlet RoAD Investigators
Publikováno v:
Alzheimer’s Research & Therapy, Vol 10, Iss 1, Pp 1-1 (2018)
Following publication of the original article [1], the author reported errors in the formatting of the table. The details of the errors are as follows:
Externí odkaz:
https://doaj.org/article/3aaa0cd884604853a09c4ce5fdef3fa5
Autor:
Ann C. Childress, Valerie Arnold, Bryan Dirks, John Shepski, Ben Adeyi, Brian Scheckner, Thomas Babcock, Robert A. Lasser, Frank A. Lopez
Publikováno v:
Journal of Attention Disorders. 21:52-61
Objective: To describe symptom rebound in children with ADHD treated with lisdexamfetamine dimesylate (LDX) or placebo. Method: During a 4-week, randomized, double-blind, placebo-controlled trial of LDX, parents/caregivers completed the Conners’ Pa
Autor:
Joseph Peuskens, Robert A. Lasser, Lars Helldin, John M. Kane, Anselmo Toledo Tronco, John P. Docherty, Henry Nasrallah
Publikováno v:
Schizophrenia Research. 96:223-231
Although the concept of remission has been widely accepted and utilized in depression and anxiety disorders, there has been much less emphasis on defining remission in schizophrenia. Recently, an expert consensus definition of remission in schizophre
Publikováno v:
Annals of Clinical Psychiatry. 19:65-71
Treatment with long-acting injectable risperidone was evaluated in young adults likely to be in the early stages of schizophrenia or schizoaffective disorder.An open-label 50-week trial included young adults (men aged 18-25 years and women aged 18-30
Autor:
Georges M. Gharabawi, Ramy A. Mahmoud, Cynthia A. Bossie, Fiona Dunbar, Carla M. Canuso, Philippe Bouhours, Amy Loescher, Ibrahim Turkoz, Robert A. Lasser, Mark Hyman Rapaport, Charles B. Nemeroff, Martin B. Keller
Publikováno v:
Neuropsychopharmacology. 31:2505-2513
Approximately one-third of persons with depression do not respond to antidepressant monotherapy. Studies suggest that atypical antipsychotic augmentation may benefit these patients. We investigated the longer-term efficacy of risperidone augmentation
Publikováno v:
Schizophrenia Research. 77:129-139
Treatment-emergent tardive dyskinesia (TD) can be a serious side effect of antipsychotic treatment. Atypical antipsychotics are associated with a lower risk for TD than are conventional agents. A long-acting atypical antipsychotic, with more stable b
Autor:
Kathleen Jarboe, Robert A. Lasser, Cynthia A. Bossie, Jean-Pierre Lindenmayer, Young Zhu, Angelika Mehnert
Publikováno v:
International Clinical Psychopharmacology. 20:213-221
Long-acting injectable antipsychotic formulations of conventional antipsychotics were developed to address the problem of partial adherence among patients with schizophrenia. Injection site pain, other skin reactions and patient satisfaction with tre
Publikováno v:
The International Journal of Neuropsychopharmacology. 8:427-438
Modern atypical antipsychotics have advantages over older neuroleptics. We hypothesize that their utility may be further enhanced by sustained drug delivery without daily oral self-dosing. This report examines the effects of a year of treatment with
Autor:
Stephen R. Marder, John M. Kane, Daniel R. Weinberger, Robert A. Lasser, Nancy C. Andreasen, William T. Carpenter
Publikováno v:
American Journal of Psychiatry. 162:441-449
New advances in the understanding of schizophrenia etiology, course, and treatment have increased interest on the part of patients, families, advocates, and professionals in the development of consensus-defined standards for clinical status and impro